Positive Patient Stories™

Paratek Pharm News

Paratek Accelerates Timing for Projected Reporting of Top-Line Data for Omadacycline Phase 3 Skin Trial

Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that it projects its ongoing pivotal Phase 3 clinical trial evaluating omadacycline for the treatment of Acute

Read More

Paratek Makes Barron's Top 9 Biotech Picks List

It’s the eve of a new year. So this seems like a great moment to look at the outlook for biotech stocks in 2016. The sector has staged a big comeback following the summertime slaughter that ravaged the industry, with the iShares Nasdaq Biotechnology ETF (IBB) climbing 19% since late September. But at Leerink, the firm’s favorite biotech names are yanked from the universe of small- and mid-cap names, a list that includes Paratek Pharmaceuticals.

Read More

Paratek Expands Leadership Team

Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) has expanded its senior leadership team. Raj Padmanabhan has joined as Vice President, Information Technology (IT). In addition, Judith Steenbergen, Ph.D has joined as Executive Director, Microbiology.

Read More

Paratek Pharmaceuticals, Inc. Reports Third Quarter 2015 Financial and Operating Results

Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK), a biopharmaceutical company focused on the development and commercialization of innovative therapies based upon

Read More

Talk with the Paratek Team

Send us an inquiry by submitting a form directly on the site or give us a call.